Clinical trials: Weight Change
Obesity
MOTIVATE Weight Loss Study
The purpose of this study is to evaluate the impact of minor variations in Incisionless Operating Platform (IOP)procedural techniques on gastric emptying, hormone levels, satiety, and weight loss in the treatment of primary…
- Trial name
- MOTIVATE (NCT01679158)
- Testing
- Using The IOP system from USGI to place suture anchors
- Where
- Spain
- Volunteers
- 18 people
- Sponsor
- USGI Medical
Mechanical Ventilation
Study of Muscle Effects of BYM338 in Mechanically Ventilated Patients
The purpose of this study is to evaluate the effect of BYM338 on muscle mass and function in Group III failure to wean patients, as compared to placebo controls.
- Trial name
- NCT01868685
- Testing
- BYM338
- Sponsor
- Novartis Pharmaceuticals
Obesity
Pivotal Aspiration Therapy With Adjusted Lifestyle Therapy Study
This research study is being performed to find out if a new device, AspireAssist Aspiration Therapy System, can help people with obesity to lose weight without causing too many side effects.
- Trial name
- PATHWAY (NCT01766037)
- Testing
- Aspiration Therapy (AspireAssist), Lifestyle Therapy
- Where
- 10 sites in United States
- Volunteers
- 171 people
- Sponsor
- Aspire Bariatrics, Inc.
Obesity
Multi-Center Pre-Bariatric Weight Loss Study
The purpose of the study is to evaluate the safety and efficacy of the GI Sleeve in patients who require weight loss prior to their Bariatric surgery.
- Trial name
- NCT00469391
- Testing
- GI Sleeve Implantable weight loss device (EndoBarrier)
- Where
- 4 sites in United States
- Volunteers
- 56 people
- Sponsor
- Morphic Medical Inc.
Cachexia
Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects
The purpose is to evaluate the safety, tolerability, and PK of NGM120 in healthy adult subjects
- Trial name
- NCT03392116
- Testing
- NGM120
- Where
- Australia
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- NGM Biopharmaceuticals, Inc
Obesity, Overweight
A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes
The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who…
- Trial name
- NCT07890376
- Testing
- LY4086940
- Where
- 46 sites in United States, Argentina
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Obesity in Diabetes, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM
This study is designed to test how well once-weekly MET097 (an ultra-long-acting GLP-1 receptor agonist) works to treat adults with obesity or overweight and type 2 diabetes mellitus (T2DM) compared to placebo.
- Trial name
- VESPER-2 (NCT06897202)
- Testing
- MET097 Injection
- Where
- 29 sites in United States
- Volunteers
- 133 people
- Sponsor
- Pfizer
Cachexia, Pancreatic Neoplasms
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia
The purpose of this study is to evaluate the effectiveness and safety of infliximab, the active ingredient in Remicade, for the treatment of cachexia in pancreatic cancer patients who are receiving chemotherapy with gemcitabine.
- Trial name
- NCT00060502
- Testing
- Infliximab; Gemcitabine
- Volunteers
- 73 people
- Sponsor
- Centocor, Inc.
Cachexia
SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)
To evaluate SUN11031 for subcutaneous injection compared to placebo in subjects with cachexia associated with Chronic Obstructive Pulmonary Disease (COPD) to determine the effect on physical performance and body composition.
- Trial name
- NCT00698828
- Testing
- SUN11031 20 μg/kg, SUN11031 40 μg/kg
- Where
- 43 sites in United States, Argentina and 4 more
- Volunteers
- 227 people
- Sponsor
- Daiichi Sankyo
Diabetes Mellitus, Weight Loss
A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function
This is a Phase I clinical study to compare the pharmacokinetics (PK) of HRS9531 Injection in participants with mild/moderate hepatic impairment and participants with normal hepatic function, and to evaluate the safety of HRS9531…
- Trial name
- NCT07540754
- Testing
- HRS9531 Injection
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Obesity
An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects
The purpose of this study is to evaluate weight reduction, safety and pharmacokinetics for certain doses of beloranib (ZGN-440 for injectable suspension) administered as twice-weekly subcutaneous injections for 12 weeks.
- Trial name
- NCT01666691
- Testing
- Beloranib
- Where
- 3 sites in Australia
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Zafgen, Inc.
Energy, Fatigue
A Clinical Trial to Assess the Effects of a Vitamin Shot on Energy Levels
This is a virtual, single-arm clinical trial that will last 30 days. Participants will drink 1 bottle of the Vitamin Energy® shot daily and complete questionnaires at baseline, Day 7, Day 14, and Day 30.
- Conditions
- Energy, Fatigue, Mood, Weight Loss
- Trial name
- NCT06019858
- Testing
- Vitamin Energy Shot
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Vitamin Energy®
Alzheimer's Disease, Dementia
Nutritional Programme for Dementia Elderly Patient
The main objective of this study is the improvement of the quality of life and state of health of elderly people with cognitive deterioration and their families through a weight loss prevention programme.
- Trial name
- NCT00479843
- Testing
- Nutritional programme
- Where
- Spain
- Volunteers
- 946 people
- Sponsor
- Société des Produits Nestlé (SPN)
Obesity, Behavior, Health
Evaluation of Brain Activity Changes After a Behavior Change Weight Loss Intervention
The aim of this study is to compare brain changes in individuals with overweight or obesity enrolled in either the Noom Healthy Weight program or a matched control.
- Conditions
- Obesity, Behavior, Health, Weight Loss
- Trial name
- NCT04522245
- Testing
- Noom Healthy Weight; mobile behavior change program for weight loss., Matched Control
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Noom Inc.
Obesity, Weight Gain
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related…
- Trial name
- NCT06439277
- Testing
- Tirzepatide
- Where
- 69 sites in United States, Argentina and 10 more
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Hunger, Weight Change
Hunger Perception and Weight-Related Outcomes Following Use of a Leptin-Supporting Dietary Supplement
This study evaluates changes in hunger perception and body composition-related measures following daily use of a commercially available dietary supplement formulated to support leptin-related metabolic signaling.
- Trial name
- NCT07442864
- Testing
- Leptin Balance Formula
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Efforia, Inc
Prediabetes, Overweight
Evaluation of Prevent in Underserved Populations
The goal of this study is to evaluate an online Diabetes Prevention Program adapted for patients with prediabetes in safety net health care settings.
- Conditions
- Prediabetes, Overweight, Obesity
- Trial name
- PUP (NCT02664064)
- Testing
- Prevent
- Where
- 3 sites in United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- Omada Health, Inc.
Weight Loss
Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.
- Trial name
- NCT07868939
- Testing
- VK2735 Oral
- Volunteers
- 560 people
- Sponsor
- Viking Therapeutics, Inc.
Cachexia, Chronic Obstructive Pulmonary Disease
Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Chronic Heart Failure and Chronic Obstructive Pulmonary Disease Patients
To test the compliance, tolerance, safety and to get preliminary insights into the efficacy of a new oral nutritional supplement (containing n-3 fatty acids, amino acids and antioxidants) designed to prevent or delay cachexia and…
- Conditions
- Cachexia, Chronic Obstructive Pulmonary Disease, Chronic Heart Failure
- Trial name
- NCT00852020
- Testing
- oral nutrition supplement, food for special medical purposes
- Where
- 4 sites in Germany, Poland
- Volunteers
- 60 people
- Sponsor
- Fresenius Kabi
Obesity
Evaluation of the Efficacy of the Composite WM Formula in Body Weight Change
This study aims to evaluate the effects of the combined formula WM Formula, used as a dietary supplement, with a focus on improvements in glycemic and lipid parameters, body composition, and gut microbiota profiles.
- Trial name
- NCT07097974
- Testing
- WM formula liquid drink
- Where
- Taiwan
- Volunteers
- healthy volunteers welcome
- Sponsor
- TCI Co., Ltd.